替雷利珠单抗联合化疗一线治疗复发或转移性鼻咽癌:RATIONALE-309三期试验三年随访
RATIONALE-309是一项双盲、安慰剂对照三期随机试验,纳入263例初治复发或转移性鼻咽癌患者,随机接受替雷利珠单抗或安慰剂联合吉西他滨和顺铂。中位随访27.5个月,替雷利珠单抗组中位无进展生存期9.6个月 vs 7.4个月(HR 0.53),中位总生存期45.3个月 vs 31.8个月(HR 0.73),安全性可接受。
要点
- 替雷利珠单抗联合化疗显著改善无进展生存期(HR 0.53)。
- 总生存期数值上延长但未达统计学显著(HR 0.73)。
- 高B细胞基因表达与更大总生存获益相关(HR 0.41)。
核心结论
- 替雷利珠单抗联合化疗一线治疗复发或转移性鼻咽癌在三年随访中维持无进展生存获益并显示有临床意义的总生存改善,安全性可接受。
研究设计与样本
- 双盲、安慰剂对照三期随机临床试验,在亚洲开展,2019年4月至2023年12月,纳入263例初治复发或转移性鼻咽癌成人患者,1:1随机接受替雷利珠单抗200 mg或安慰剂每3周联合吉西他滨和顺铂4-6周期。
主要发现
- 替雷利珠单抗组中位无进展生存期9.6个月(95%CI 7.6-11.6),安慰剂组7.4个月(95%CI 5.6-7.6),HR 0.53(95%CI 0.39-0.71)。
- 替雷利珠单抗组中位总生存期45.3个月(95%CI 33.4-不可估计),安慰剂组31.8个月(95%CI 25.0-不可估计),HR 0.73(95%CI 0.51-1.05)。
- 秩保持结构失效时间分析HR 0.56(95%CI 0.27-1.19),两阶段交叉校正分析HR 0.62(95%CI 0.40-0.97)。
- 高B细胞基因表达与更大总生存获益相关(HR 0.41,95%CI 0.23-0.74)。
关键数值与推荐
- 替雷利珠单抗组治疗中出现的不良事件发生率100%(133/133),安慰剂组99.2%(129/130),3级及以上不良事件发生率相当。
- 免疫介导不良事件在替雷利珠单抗组更常见(53.4% vs 37.7%),但多为1或2级。
临床怎么用
- 对于初治复发或转移性鼻咽癌患者,可考虑替雷利珠单抗联合吉西他滨和顺铂作为一线治疗选择。
- 高B细胞基因表达可能作为总生存获益的潜在生物标志物,但需进一步验证。
局限性
- 总生存期差异未达统计学显著(HR 0.73,95%CI 0.51-1.05)。
- 安慰剂组疾病进展后可交叉接受替雷利珠单抗单药治疗,可能稀释总生存获益。
- 研究在亚洲进行,结果外推至其他地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nasopharyngeal carcinoma (NPC) is a major health concern in Asia, and treatment options for recurrent or metastatic disease are limited. Immunotherapy plus chemotherapy has shown promise, but long-term data are needed to guide first-line treatment. OBJECTIVE: To evaluate the 3-year efficacy and safety of tislelizumab plus chemotherapy vs placebo plus chemotherapy in participants with recurrent or metastatic NPC and explore potential biomarkers of treatment response. DESIGN, SETTING, AND PARTICIPANTS: The RATIONALE-309 trial was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted in Asia from April 2019 to December 2023. Treatment-naive adults with histologically or cytologically confirmed recurrent or metastatic NPC were included. Data were analyzed from December 2023 to January 2024. INTERVENTIONS: Participants were randomized 1:1 to receive tislelizumab, 200 mg, intravenously or placebo every 3 weeks, both with gemcitabine and cisplatin for 4 to 6 cycles. Participants in the placebo arm could cross over to tislelizumab monotherapy at disease progression. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) assessed by an independent review committee. The primary hypothesis (PFS superiority for tislelizumab vs placebo) was specified in the protocol prior to data collection. Secondary end points included overall survival (OS), PFS after next-line therapy, and safety. RESULTS: Of 263 included participants, 206 (78.3%) were male, and the median (range) age was 50 (23-74) years; the median (range) follow-up was 27.5 (0.1-53.0) months. A total of 131 were randomized to the tislelizumab group and 132 to the placebo group. Tislelizumab plus chemotherapy demonstrated improved PFS vs placebo plus chemotherapy (median PFS, 9.6 months [95% CI, 7.6-11.6] vs 7.4 months [95% CI, 5.6-7.6]; hazard ratio [HR], 0.53; 95% CI, 0.39-0.71). The median OS was 45.3 months (95% CI, 33.4 to not estimable) vs 31.8 months (95% CI, 25.0 to not estimable), respectively (HR, 0.73; 95% CI, 0.51-1.05). Rank-preserving structural failure time analysis (HR, 0.56; 95% CI, 0.27-1.19) and 2-stage crossover-adjusted analysis (HR, 0.62; 95% CI, 0.40-0.97) showed greater OS benefit. Treatment-emergent adverse events occurred in 133 of 133 participants (100%) in the tislelizumab arm and 129 of 130 participants (99.2%) in the placebo arm, with comparable grade 3 or higher adverse event rates. Immune-mediated adverse events were more frequent with tislelizumab (71 [53.4%] vs 49 [37.7%]) but mostly of grades 1 or 2. High B-cell gene expression was associated with greater OS benefit (HR, 0.41; 95% CI, 0.23-0.74). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the RATIONALE-309 randomized clinical trial, after 3 years of follow-up, tislelizumab plus chemotherapy provided sustained PFS and meaningful OS improvement vs placebo plus chemotherapy in recurrent or metastatic NPC, with an acceptable safety profile. Greater benefit was observed in participants with activated immune signatures, especially high B-cell expression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03924986.
引用
- Yang Y, Yen CJ, Pan J, et al. First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41746630. doi:10.1001/jamaoncol.2026.0020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。